Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

被引：0
作者：
Ganesh Raghu
Mark J. Hamblin
A. Whitney Brown
Jeffrey A. Golden
Lawrence A. Ho
Marlies S. Wijsenbeek
Martina Vasakova
Alberto Pesci
Danielle E. Antin-Ozerkis
Keith C. Meyer
Michael Kreuter
Tracy Burgess
Nikhil Kamath
Francis Donaldson
Luca Richeldi
机构：
[1] University of Washington,Center for Interstitial Lung Diseases, Department of Medicine and Laboratory Medicine
[2] University of Kansas Medical Center,Pulmonary and Critical Care Medicine
[3] Inova Fairfax Hospital,Inova Advanced Lung Disease and Transplant Program
[4] University of California,Department of Medicine
[5] San Francisco,Department of Respiratory Medicine
[6] Erasmus MC,Department of Respiratory Medicine
[7] University Medical Center,School of Medicine and Surgery
[8] First Faculty of Medicine of Charles University and Thomayer Hospital,Pulmonary, Critical Care, and Sleep Medicine
[9] University of Milano-Bicocca,Department of Medicine, Division of Pulmonary and Critical Care
[10] ASST-Monza,Center for Interstitial and Rare Lung Diseases, Department of Pneumology
[11] Yale School of Medicine,undefined
[12] University of Wisconsin School of Medicine and Public Health,undefined
[13] Thoraxklinik,undefined
[14] University of Heidelberg and German Center for Lung Research,undefined
[15] Genentech,undefined
[16] Inc.,undefined
[17] Roche Products Ltd.,undefined
[18] Fondazione Policlinico Universitario A Gemelli IRCCS,undefined
[19] Università Cattolica del Sacro Cuore,undefined
来源：
Respiratory Research | / 23卷
关键词：
Recombinant human pentraxin-2 (rhPTX-2); Idiopathic pulmonary fibrosis (IPF); Long-term; Safety; Open-label extension; Forced vital capacity (FVC); 6-minute walk distance (6MWD);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 109 条
  • [1] Raghu G(2018)Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Am J Respir Crit Care Med 198 e44-e68
  • [2] Remy-Jardin M(2018)Physiology of the lung in idiopathic pulmonary fibrosis Eur Respir Rev 27 59-S24
  • [3] Myers JL(2019)The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry Respir Res 20 S17-2092
  • [4] Richeldi L(2017)Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis J Manag Care Spec Pharm 23 1902279-2082
  • [5] Ryerson CJ(2019)Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials BMJ Open Respir Res 6 2083-2307
  • [6] Lederer DJ(2020)Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Eur Respir J 56 2071-664
  • [7] Plantier L(2014)A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2299-824
  • [8] Cazes A(2014)Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 1701209-21.e7
  • [9] Dinh-Xuan AT(2018)Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial JAMA 319 657-162
  • [10] Bancal C(2017)Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years Eur Respir J 50 788-1740
12345678910